Therapeutic strategies in epithelial ovarian cancer

go back to reference Kurman RJ, Shih Ie M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010, 34: 433-443. 10.1097/PAS.0b013e3181cf3d79.PubMedCentralCrossRefPubMed Kurman RJ, Shih Ie M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010, 34: 433-443. 10.1097/PAS.0b013e3181cf3d79.PubMedCentralCrossRefPubMed

go back to reference Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999, 93: 21-24. 10.1016/S0029-7844(98)00334-2.CrossRefPubMed Rubin SC, Randall TC, Armstrong KA, Chi DS, Hoskins WJ: Ten-year follow-up of ovarian cancer patients after second-look laparotomy with negative findings. Obstet Gynecol. 1999, 93: 21-24. 10.1016/S0029-7844(98)00334-2.CrossRefPubMed

go back to reference Hennessy BT, Coleman RL, Markman M: Ovarian cancer. Lancet. 2009, 374: 1371-82. 10.1016/S0140-6736(09)61338-6.CrossRefPubMed Hennessy BT, Coleman RL, Markman M: Ovarian cancer. Lancet. 2009, 374: 1371-82. 10.1016/S0140-6736(09)61338-6.CrossRefPubMed

go back to reference Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed 1 model based on orphological and molecular genetic analysis. Am J Pathol. 2004, 164: 1511-1518. 10.1016/S0002-9440(10)63708-X.CrossRefPubMed Shih Ie M, Kurman RJ: Ovarian tumorigenesis: a proposed 1 model based on orphological and molecular genetic analysis. Am J Pathol. 2004, 164: 1511-1518. 10.1016/S0002-9440(10)63708-X.CrossRefPubMed

go back to reference Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M: Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008, 198: 351-356. 10.1016/j.ajog.2008.01.005.PubMedCentralCrossRefPubMed Kurman RJ, Visvanathan K, Roden R, Wu TC, Shih Ie M: Early detection and treatment of ovarian cancer: shifting from early stage to minimal volume of disease based on a new model of carcinogenesis. Am J Obstet Gynecol. 2008, 198: 351-356. 10.1016/j.ajog.2008.01.005.PubMedCentralCrossRefPubMed

go back to reference Cho KR, Shih Ie M: Ovarian cancer. Annu Rev Pathol. 2009, 4: 287-313. 10.1146/annurev.pathol.4.110807.092246.PubMedCentralCrossRefPubMed Cho KR, Shih Ie M: Ovarian cancer. Annu Rev Pathol. 2009, 4: 287-313. 10.1146/annurev.pathol.4.110807.092246.PubMedCentralCrossRefPubMed

go back to reference Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008, 9: 1191-10.1016/S1470-2045(08)70308-5. 7. ReviewPubMedCentralCrossRefPubMed Dubeau L: The cell of origin of ovarian epithelial tumours. Lancet Oncol. 2008, 9: 1191-10.1016/S1470-2045(08)70308-5. 7. ReviewPubMedCentralCrossRefPubMed

go back to reference Trimbos JB, Parmar M, Vergote I, et al: International Collaborative Ovarian Neoplasm trial and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003, 95: 105-112.CrossRefPubMed Trimbos JB, Parmar M, Vergote I, et al: International Collaborative Ovarian Neoplasm trial and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. J Natl Cancer Inst. 2003, 95: 105-112.CrossRefPubMed

go back to reference Ramirez I, Chon HS, Apte SM: The Role of Surgery in the Management of Epithelial Ovarian Cancer: Role of Surgery. http://www.medscape.com/viewarticle/738258_3 Ramirez I, Chon HS, Apte SM: The Role of Surgery in the Management of Epithelial Ovarian Cancer: Role of Surgery. http://​www.​medscape.​com/​viewarticle/​738258_​3

go back to reference Vergote I, Trope CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010, 363: 943-953. 10.1056/NEJMoa0908806.CrossRefPubMed Vergote I, Trope CG, Amant F, et al: Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010, 363: 943-953. 10.1056/NEJMoa0908806.CrossRefPubMed

go back to reference Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991, 9: 1801-1805.PubMed Markman M, Reichman B, Hakes T, et al: Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol. 1991, 9: 1801-1805.PubMed

go back to reference Pisano C, Bruni GS, Facchini G, Marchetti C, Pignata S: Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag. 2009, 5: 421-426.PubMedCentralPubMed Pisano C, Bruni GS, Facchini G, Marchetti C, Pignata S: Treatment of recurrent epithelial ovarian cancer. Ther Clin Risk Manag. 2009, 5: 421-426.PubMedCentralPubMed

go back to reference Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003, 361: 2099-2106.CrossRefPubMed Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet. 2003, 361: 2099-2106.CrossRefPubMed

go back to reference Monk BJ, Herzog TJ, Kaye SB, et al: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010, 28: 3107-3114. 10.1200/JCO.2009.25.4037.CrossRefPubMed Monk BJ, Herzog TJ, Kaye SB, et al: Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer. J Clin Oncol. 2010, 28: 3107-3114. 10.1200/JCO.2009.25.4037.CrossRefPubMed

go back to reference Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993, 72: 3671-3675. 10.1002/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>3.0.CO;2-U.CrossRefPubMed Vaage J, Donovan D, Mayhew E, Abra R, Huang A: Therapy of human ovarian carcinoma xenografts using doxorubicin encapsulated in sterically stabilized liposomes. Cancer. 1993, 72: 3671-3675. 10.1002/1097-0142(19931215)72:12<3671::AID-CNCR2820721219>3.0.CO;2-U.CrossRefPubMed

go back to reference Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010, 28: 3323-3329. 10.1200/JCO.2009.25.7519.CrossRefPubMed Pujade-Lauraine E, Wagner U, Aavall-Lundqvist E, et al: Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse. J Clin Oncol. 2010, 28: 3323-3329. 10.1200/JCO.2009.25.7519.CrossRefPubMed

go back to reference Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000, 88: 2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.CrossRefPubMed Sugiyama T, Kamura T, Kigawa J, et al: Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer. 2000, 88: 2584-2589. 10.1002/1097-0142(20000601)88:11<2584::AID-CNCR22>3.0.CO;2-5.CrossRefPubMed

go back to reference T Enomoto CK, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A, Murata Y: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin?. Proc Am Soc Clin Oncol. 2003, 22: 477s-(abstr#1797) T Enomoto CK, Yamasaki M, Sugita N, Otsuki Y, Ikegami H, Matsuzaki N, Yamada T, Wakimoto A, Murata Y: Is clear cell carcinoma and mucinous carcinoma of the ovary sensitive to combination chemotherapy with paclitaxel and carboplatin?. Proc Am Soc Clin Oncol. 2003, 22: 477s-(abstr#1797)

go back to reference Takakura S, Takano M, Takahashi F, et al: Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010, 20: 240-247. 10.1111/IGC.0b013e3181cafb47.CrossRefPubMed Takakura S, Takano M, Takahashi F, et al: Randomized phase II trial of paclitaxel plus carboplatin therapy versus irinotecan plus cisplatin therapy as first-line chemotherapy for clear cell adenocarcinoma of the ovary: a JGOG study. Int J Gynecol Cancer. 2010, 20: 240-247. 10.1111/IGC.0b013e3181cafb47.CrossRefPubMed

go back to reference Yoshino K, Enomoto T, Fujita M, Ueda Y, Kimura T, Kobayashi E, Tsutsui T, Kimura T: Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Int J Clin Oncol. 2011, Yoshino K, Enomoto T, Fujita M, Ueda Y, Kimura T, Kobayashi E, Tsutsui T, Kimura T: Salvage chemotherapy for recurrent or persistent clear cell carcinoma of the ovary: a single-institution experience for a series of 20 patients. Int J Clin Oncol. 2011,

go back to reference McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998, 25: 340-348.PubMed McGuire WP, Ozols RF: Chemotherapy of advanced ovarian cancer. Semin Oncol. 1998, 25: 340-348.PubMed

go back to reference Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093/jnci/92.9.699.CrossRefPubMed Piccart MJ, Bertelsen K, James K, et al: Randomized intergroup trial of cisplatin paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000, 92: 699-708. 10.1093/jnci/92.9.699.CrossRefPubMed

go back to reference Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of 1 cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000, 18: 106-115.PubMed Muggia FM, Braly PS, Brady MF, et al: Phase III randomized study of 1 cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2000, 18: 106-115.PubMed

go back to reference Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.CrossRefPubMed Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006, 354: 34-43. 10.1056/NEJMoa052985.CrossRefPubMed

go back to reference Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G: Chemotherapy in epithelial ovarian cancer. Cancer Lett. 2011, 303: 73-83. 10.1016/j.canlet.2011.01.026.CrossRefPubMed Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G: Chemotherapy in epithelial ovarian cancer. Cancer Lett. 2011, 303: 73-83. 10.1016/j.canlet.2011.01.026.CrossRefPubMed

go back to reference Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999, 17: 2341-2354.PubMed Chan S, Friedrichs K, Noel D, et al: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol. 1999, 17: 2341-2354.PubMed

go back to reference Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005, 23: 5542-5551. 10.1200/JCO.2005.02.027.CrossRefPubMed Jones SE, Erban J, Overmoyer B, et al: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol. 2005, 23: 5542-5551. 10.1200/JCO.2005.02.027.CrossRefPubMed

go back to reference Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur J Cancer. 1997, 33: 2167-2170. 10.1016/S0959-8049(97)00363-8.CrossRefPubMed Kaye SB, Piccart M, Aapro M, Francis P, Kavanagh J: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer-an updated overview. Eur J Cancer. 1997, 33: 2167-2170. 10.1016/S0959-8049(97)00363-8.CrossRefPubMed

go back to reference Rose PG, Blessing JA, Ball HG, et al: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003, 88: 130-135. 10.1016/S0090-8258(02)00091-4.CrossRefPubMed Rose PG, Blessing JA, Ball HG, et al: A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2003, 88: 130-135. 10.1016/S0090-8258(02)00091-4.CrossRefPubMed

go back to reference Vasey PA, Atkinson R, Coleman R, et al: Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer. 2001, 84: 170-178. 10.1054/bjoc.2000.1572.PubMedCentralCrossRefPubMed Vasey PA, Atkinson R, Coleman R, et al: Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br J Cancer. 2001, 84: 170-178. 10.1054/bjoc.2000.1572.PubMedCentralCrossRefPubMed

go back to reference Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004, 96: 1682-1691. 10.1093/jnci/djh323.CrossRefPubMed Vasey PA, Jayson GC, Gordon A, et al: Phase III randomized trial of docetaxel carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004, 96: 1682-1691. 10.1093/jnci/djh323.CrossRefPubMed

go back to reference Matsuo K, Lin YG, Roman LD, Sood AK: Overcoming Platinum Resistance in Ovarian Carcinoma. Expert Opin Investig Drugs. 2010, 19: 1339-1354. 10.1517/13543784.2010.515585.PubMedCentralCrossRefPubMed Matsuo K, Lin YG, Roman LD, Sood AK: Overcoming Platinum Resistance in Ovarian Carcinoma. Expert Opin Investig Drugs. 2010, 19: 1339-1354. 10.1517/13543784.2010.515585.PubMedCentralCrossRefPubMed

go back to reference Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008, 8: 579-591. 10.1038/nrc2403.CrossRefPubMed Ellis LM, Hicklin DJ: VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008, 8: 579-591. 10.1038/nrc2403.CrossRefPubMed

go back to reference Raspollini MR, Castiglione F, Garbini F, et al: Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol. 2005, 13: 135-142. 10.1177/106689690501300202.CrossRefPubMed Raspollini MR, Castiglione F, Garbini F, et al: Correlation of epidermal growth factor receptor expression with tumor microdensity vessels and with vascular endothelial growth factor expression in ovarian carcinoma. Int J Surg Pathol. 2005, 13: 135-142. 10.1177/106689690501300202.CrossRefPubMed

go back to reference Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX: Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011, 365: 2473-83. 10.1056/NEJMoa1104390.CrossRefPubMed Burger RA, Brady MF, Bookman MA, Fleming GF, Monk BJ, Huang H, Mannel RS, Homesley HD, Fowler J, Greer BE, Boente M, Birrer MJ, Liang SX: Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011, 365: 2473-83. 10.1056/NEJMoa1104390.CrossRefPubMed

go back to reference Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM: ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011, 365: 2484-96. 10.1056/NEJMoa1103799.CrossRefPubMed Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, Stähle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MK, Oza AM: ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med. 2011, 365: 2484-96. 10.1056/NEJMoa1103799.CrossRefPubMed

go back to reference Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi J, Parmar H, Nycum LR, Sovak MA: J Clin Oncol. 2011, 29: Memorial Sloan-Kettering Cancer Center, New York, NY; Florida Hospital Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando, FL; Yale University School of Medicine, New Haven, CT; Northwest Cancer Specialists, Vancouver, WA; Genentech Inc., South San Francisco, CA; Forsyth Regional Cancer Center, Winston-Salem, NC. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (suppl; abstr LBA5007) Aghajanian C, Finkler NJ, Rutherford T, Smith DA, Yi J, Parmar H, Nycum LR, Sovak MA: J Clin Oncol. 2011, 29: Memorial Sloan-Kettering Cancer Center, New York, NY; Florida Hospital Gynecologic Oncology, Florida Hospital Cancer Institute, Orlando, FL; Yale University School of Medicine, New Haven, CT; Northwest Cancer Specialists, Vancouver, WA; Genentech Inc., South San Francisco, CA; Forsyth Regional Cancer Center, Winston-Salem, NC. OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). (suppl; abstr LBA5007)

go back to reference Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010, 10: 293-301. 10.1038/nrc2812.PubMedCentralCrossRefPubMed Rouleau M, Patel A, Hendzel MJ, Kaufmann SH, Poirier GG: PARP inhibition: PARP1 and beyond. Nat Rev Cancer. 2010, 10: 293-301. 10.1038/nrc2812.PubMedCentralCrossRefPubMed

go back to reference Itamochi H: Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem. 2010, 1: 209-220. 10.4331/wjbc.v1.i7.209.PubMedCentralCrossRefPubMed Itamochi H: Targeted therapies in epithelial ovarian cancer: Molecular mechanisms of action. World J Biol Chem. 2010, 1: 209-220. 10.4331/wjbc.v1.i7.209.PubMedCentralCrossRefPubMed

go back to reference King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003, 302: 643-646. 10.1126/science.1088759.CrossRefPubMed King MC, Marks JH, Mandell JB: Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003, 302: 643-646. 10.1126/science.1088759.CrossRefPubMed

go back to reference Press JZ, De Luca A, Boyd N, et al: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008, 8: 17-10.1186/1471-2407-8-17.PubMedCentralCrossRefPubMed Press JZ, De Luca A, Boyd N, et al: Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities. BMC Cancer. 2008, 8: 17-10.1186/1471-2407-8-17.PubMedCentralCrossRefPubMed

go back to reference Helleday T: The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011, 5: 387-93. 10.1016/j.molonc.2011.07.001.CrossRefPubMed Helleday T: The underlying mechanism for the PARP and BRCA synthetic lethality: clearing up the misunderstandings. Mol Oncol. 2011, 5: 387-93. 10.1016/j.molonc.2011.07.001.CrossRefPubMed

go back to reference Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase 1 in tumors from BRCA mutation carriers. N Engl J Med. 2009, 361: 123-134. 10.1056/NEJMoa0900212.CrossRefPubMed Fong PC, Boss DS, Yap TA, et al: Inhibition of poly(ADP-ribose) polymerase 1 in tumors from BRCA mutation carriers. N Engl J Med. 2009, 361: 123-134. 10.1056/NEJMoa0900212.CrossRefPubMed

go back to reference Fong PC, Yap TA, Boss DS, et al: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010, 28: 2512-2519. 10.1200/JCO.2009.26.9589.CrossRefPubMed Fong PC, Yap TA, Boss DS, et al: Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval. J Clin Oncol. 2010, 28: 2512-2519. 10.1200/JCO.2009.26.9589.CrossRefPubMed